Boucher J M, Racine N, Thanh T H, Rahme E, Brophy J, LeLorier J, Théroux P
Département de Médecine, Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montreal, Que.
CMAJ. 2001 May 1;164(9):1285-90.
Recent guidelines have acknowledged that thrombolysis decreases mortality from acute myocardial infarction (AMI) independently of age. The purpose of this study was to determine the age-related rates of thrombolytic administration and in-hospital mortality and the variables related to the use of thrombolytic therapy for patients with AMI.
A prospective cohort analysis involved a registry of 44 acute care Quebec hospitals that enrolled 3741 patients with AMI between January 1995 and May 1996. The main outcomes of interest were crude and adjusted age-related in-hospital mortality rates and rates of use of thrombolytic therapy.
In-hospital mortality rates increased dramatically with age from 2.1% in patients with AMI who were less than 55 years of age to 26.3% in those who were 85 years of age or older. Overall, 35.8% of the patients received thrombolysis. There was a pronounced inverse gradient in the use of thrombolysis with age, ranging from 46.2% in the youngest age group (< 55 years) to 9.5% in the oldest group (> or = 85 years). After adjustment for potential confounders, the older patients remained significantly less likely to receive thrombolytic therapy. Compared with patients who were less than 55 years of age, the odds ratio of receiving thrombolytic therapy was 0.68 (95% confidence interval [CI] 0.52-0.89) for patients aged 65-74 years, 0.48 (95% CI 0.35-0.65) for patients aged 75-84 years and 0.13 (95% CI 0.06-0.26) for patients aged 85 years or more. Other variables related to thrombolytic therapy were diabetes (odds ratio [OR] 0.77, 95% CI 0.59-1.00), cerebrovascular disease (OR 0.46, 95% CI 0.30-0.72), angina (OR 0.73, 95% CI 0.56-0.95), typical chest pain (OR 2.56, 95% CI 1.88-3.47); ST elevation (OR 8.93, 95% CI 7.24-11.00), Q wave MI (OR 5.26, 95% CI 4.20-6.60) and increased length of time between onset of symptoms and arrival at hospital.
Age is an important independent predictor of in-hospital mortality and lower thrombolytic use following AMI. Other studies are required to further evaluate the appropriateness of thrombolytic therapy for elderly patients.
近期指南已承认,溶栓治疗可独立于年龄降低急性心肌梗死(AMI)的死亡率。本研究的目的是确定与年龄相关的溶栓治疗使用率和住院死亡率,以及与AMI患者使用溶栓治疗相关的变量。
一项前瞻性队列分析涉及魁北克44家急症医院的登记数据,这些医院在1995年1月至1996年5月期间纳入了3741例AMI患者。主要关注的结果是与年龄相关的粗住院死亡率和调整后的住院死亡率,以及溶栓治疗的使用率。
住院死亡率随年龄显著增加,从年龄小于55岁的AMI患者中的2.1%增至85岁及以上患者中的26.3%。总体而言,35.8%的患者接受了溶栓治疗。溶栓治疗的使用率随年龄呈现明显的反向梯度,从最年轻年龄组(<55岁)的46.2%到最年长组(≥85岁)的9.5%。在对潜在混杂因素进行调整后,老年患者接受溶栓治疗的可能性仍然显著较低。与年龄小于55岁的患者相比,65 - 74岁患者接受溶栓治疗的比值比为0.68(95%置信区间[CI] 0.52 - 0.89),75 - 84岁患者为0.48(95% CI 0.35 - 0.65),85岁及以上患者为0.13(95% CI 0.06 - 0.26)。与溶栓治疗相关的其他变量包括糖尿病(比值比[OR] 0.77,95% CI 0.59 - 1.00)、脑血管疾病(OR 0.46,95% CI 0.30 - 0.72)、心绞痛(OR 0.73,95% CI 0.56 - 0.95)、典型胸痛(OR 2.56,95% CI 1.88 - 3.47);ST段抬高(OR 8.93,95% CI 7.24 - 11.00)、Q波心肌梗死(OR 5.26,95% CI 4.20 - 6.60)以及症状发作到入院时间的延长。
年龄是AMI后住院死亡率和较低溶栓治疗使用率的重要独立预测因素。需要进一步开展其他研究以评估老年患者溶栓治疗的适宜性。